Biodesix To Present Data On Development Of New Ultra-Sensitive ESR1 Test For Initial Detection And Monitoring Of Mutations In HR+/HER2- Advanced Breast Cancers At SABCS

Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostics solutions company, announces several poster presentations on lung cancer diagnostics and new research on breast cancer diagnostics at upcoming scientific meetings.

The company will also present data on the development of a new ultra-sensitive ESR1 test for initial detection and monitoring of the mutations in HR+/HER2- advanced breast cancers at the San Antonio Breast Cancer Symposium, December 9 -12, San Antonio, TX. This innovative test is now available to biopharmaceutical customers as part of the company's Development Services offering:

• Poster Session 4, PS4-02-29: Development of an ultra-sensitive droplet digital PCR test for monitoring ESR1 variants in liquid biopsies.
  
  Authors: Leisa Jackson (Biodesix Staff Scientist and Presenter), Helen Halpin, and Gary Pestano, PhD.